
OUR MISSION
To develop targeted cancer therapeutics that provide better outcomes for patients
We’re building an Australian company with an ambitious vision to revolutionise cancer treatment across the globe. With exceptional expertise in drug discovery and pre-clinical development, a pipeline of promising drug candidates, and a team comprised of experienced executives, Aucentra is poised for success.
Our next step is to expand our clinical activities to take our discoveries into Phase II clinical trials.
OUR MANAGEMENT TEAM & ADVISORY BOARD

Professor Shudong Wang
Founder & Managing Director
- Head of Drug Discovery and Development, University of South Australia
- Inventor of >90 patents
- >150 publications
- Former Head of Chemistry and Oncology Drug Discovery, Cyclacel, UK
- Founder of two biotech companies
- Consultant to multiple pharma companies

Dr Paul Wabnitz
Clinical Research & Development Director
- Medical Director and experienced Drug Development Consultant in Translational Medicine, Drug Design and Medicinal Chemistry.
- Expertise in toxicology, clinical trial design, planning & execution of a first-in-human clinical study.
- Extensive experience with complex novel drugs and targeted combination therapy.

Dr Matt Chong
Business Development Director
- Over 15 years’ experience in commercial development and strategic management
- Over 20 years’ experience working across industry, academia and government
- PhD in Biochemistry with expertise in protein chemistry and signal transduction biology

Dina Spivak
Operations Manager
- Over 15 years’ experience in the pharmaceutical industry including, Regulatory affairs, QA, Operations and management, medicinal chemistry, drug research, analytical development for US, EU and International markets.
- Passionate about working effectively in a cross culture and cross functional complex environment.

Mr Jun Liu
Director
- Board Member, Changzhou Qianhong Bio-pharma Co. Ltd
- Senior Biochemical Engineer
- 30 years’ experience in drug R&D and manufacturing
- Expert in industrial transformation of drugs from laboratory to production

Dr Jurgen Michaelis
Advisory Board Chair
-
30 years’ senior management in life sciences
-
Advisor on the formation of >80 companies
-
Raised >$200 million capital
-
Listed 2 companies on stock exchange
-
Founder and Chair of industry VC fund

Professor Ian Olver AM
Advisory Board Member
- MBBS MD PhhD FRACP FAChPM MRACMA
- Medical oncologist and bio-ethicist
- Chaired 6 national cancer and ethics committees
- Former CEO, Cancer Council Australia
- Former Clinical Director, Royal Adelaide Hospital Cancer Centre
- Established 2 clinical centers
- >300 publications

Dr David Fuller
Advisory Board Member
- Senior Vice President, Clinical Development, Syneos Health
- International leader in biopharmaceutical development
- >30 years’ experience in clinical trials and drug evaluation
- Led 5 product approvals
- Worked for major international companies inc. Pfizer, Roche and Genzyme

Dr Jose Iglesias
Advisory Board Member
- Independent oncology consultant, Director, APEX Oncology Consulting
- International leader in clinical pharmaceutical development
- >20 years’ experience as a Chief Medical Advisor or Director in the field of oncology
- Led a range of international clinical trials
- Worked for major international companies such as Eli Lily and AMGEN, as well as start-up and mid-tier biotech companies
OUR CONSUMER ADVISORY GROUP

John Clements

Dr Marilyn Mackinder

Dahlia Matkovic

Sarah Tinney

Chris Tretheway
Our Consumer Advisory Group exists to gain input from cancer survivors, as well as others whose lives have been touched by the disease, on our proposed research activities and findings, to ensure that issues important to consumers are identified, prioritised and shared.
Advisory Group members have the opportunity to contribute to our research and be the voice for cancer patients, an important interface between our scientists and the community, ensuring our projects remain focused on research that is impactful and can make a real difference for patients.